952511-74-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3-methylbenzene-1,2-diamine is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure allows for the creation of a range of medicinal compounds, contributing to the development of new drugs and therapeutic agents.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 4-Bromo-3-methylbenzene-1,2-diamine is utilized as a key intermediate in the synthesis of organic dyes and pigments. Its chemical properties enable the production of a variety of colorants used in different applications, including textiles, plastics, and printing inks.
Used in Polymer Material Synthesis:
4-Bromo-3-methylbenzene-1,2-diamine is also employed in the synthesis of polymer materials. Its presence in the polymerization process can influence the properties of the resulting polymers, such as their stability, color, and other functional characteristics, making it an important component in material science.
Overall, 4-Bromo-3-methylbenzene-1,2-diamine is a valuable chemical intermediate with diverse applications across multiple industries, highlighting its importance in modern chemical synthesis and material development.

Upstream product

• 55289-36-6 3-bromo-2-methylaniline 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 570-24-1 2-Methyl-6-nitroaniline 
• 601-87-6 3-methyl-2-nitroaniline 
• 854624-54-7 4-bromo-3-methyl-2-nitro-aniline 
• 1325729-87-0 N-(3-bromo-2-methyl-6-nitrophenyl)-2,2,2-trifluoroacetamide 
• 290353-57-0 1-bromo-2-methyl-3,4-dinitrobenzene 

Downstream Products

• 952511-48-7 5-bromo-4-methyl-1H-benzo[d]imidazole 
• 952511-70-5 4-methyl-1H-benzo[d]imidazole-5-carbonitrile 

Relevant academic research and scientific papers

Azacycle diketone compound and preparation method thereof (by machine translation)

The invention provides a azacyclodiketone compound which is characterized by being a compound represented by the following structure. The compound has inhibitory activity on cap-dependent endonuclease. (by machine translation)

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

HETERO COMPOUND

[Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P1 a